Survival outcomes for HER2-low breast cancer: Danish national data
DOI:
https://doi.org/10.2340/1651-226X.2024.41280Keywords:
HER2-low breast cancer, Survival analysis, HER2-low prognosis, HER2, DBCGAbstract
Background and purpose: We investigated the prognosis of breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2), as previous studies have found varying impacts on survival of HER2-low BC compared with HER2 0 BC (HER2 IHC score of 0). HER2-low is defined as a score of 1+ or 2+ in an immunohistochemical (IHC) assay without HER2 gene amplification.
Materials and methods: Patients with HER2 0 or HER2-low BC from the national Danish Breast Cancer Group database were examined by multivariable survival analysis in a retrospective noninterventional investigation. Patients were grouped as either HER2 0 or HER2-low. The primary endpoint was time to recurrence (TR), and the secondary endpoints were overall survival (OS) and distant recurrence-free interval (DRFI).
Results: 41,610 patients were included (12,981 with HER2 0 BC and 28,629 with HER2-low BC). HER2-low BC was associated with a lower risk of recurrence (hazard ratio [HR]: 0.92, p = 0.03). Regarding secondary endpoints, HER2-low disease was linked to improved overall OS (HR: 0.94, p = 0.02). No statistically significant effect of HER2-low was found for DRFI, along with no differential effect of HER2-low according to estrogen receptor (ER) status.
Interpretation: HER2-low BC was found to show an improved HR for OS and DRFI compared with HER2 0 BC; however, further studies are need to establish whether it represents a separate biological entity.
Downloads
References
Kos Z, Nielsen TO, Laenkholm AV. Breast cancer histopathology in the age of molecular oncology. Cold Spring Harb Perspect Med. 2024;14(6).
https://doi.org/10.1101/cshperspect.a041647 DOI: https://doi.org/10.1101/cshperspect.a041647
Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
https://doi.org/10.1038/nature11412 DOI: https://doi.org/10.1038/nature11412
Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA. Subtypes of breast cancer. Breast Cancer. 2022;31–42.
https://doi.org/10.36255/exon-publications-breast-cancer-subtypes DOI: https://doi.org/10.36255/exon-publications-breast-cancer-subtypes
Fehrenbacher L, Cecchini RS, Geyer CE, Rastogi P, Costantino JP, Atkins JN, et al. NSABP B-47/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol. 2020;38(5):444–53.
https://doi.org/10.1200/JCO.19.01455 DOI: https://doi.org/10.1200/JCO.19.01455
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):182–91.
https://doi.org/10.1126/science.3798106 DOI: https://doi.org/10.1126/science.3798106
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.
https://doi.org/10.1126/science.2470152 DOI: https://doi.org/10.1126/science.2470152
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9–20. DOI: https://doi.org/10.1056/NEJMoa2203690
https://www.nejm.org/doi/10.1056/NEJMoa2203690
Molinelli C, Jacobs F, Agostinetto E, Marta GN, Ceppi M, Bruzzone M, et al. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2023;41(16_suppl):1104.
https://doi.org/10.1200/JCO.2023.41.16_suppl.1104 DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.1104
Tarantino P, Viale G, Press MF, Hu X, Llorca FP, Bardia A, et al. ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34:645–59.
https://doi.org/10.1016/j.annonc.2023.05.008 DOI: https://doi.org/10.1016/j.annonc.2023.05.008
Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. 2022;8:1177–83.
https://doi.org/10.1001/jamaoncol.2022.2286 DOI: https://doi.org/10.1001/jamaoncol.2022.2286
Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel). 2021;13(11)2824.
https://doi.org/10.3390/cancers13112824 DOI: https://doi.org/10.3390/cancers13112824
de Moura Leite L, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimarães PT, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat. 2021;190(1):155–63.
https://doi.org/10.1007/s10549-021-06365-7 DOI: https://doi.org/10.1007/s10549-021-06365-7
Baez-Navarro X, van Bockstal MR, Andrinopoulou ER, van Deurzen CHM. HER2-low breast cancer: incidence, clinicopathologic features, and survival outcomes from real-world data of a large nationwide cohort. Mod Pathol. 2023;36(4):100087.
https://doi.org/10.1016/j.modpat.2022.100087 DOI: https://doi.org/10.1016/j.modpat.2022.100087
Tan RSYC, Ong WS, Lee KH, Lim AH, Park S, Park YH, et al. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Med. 2022;20(1):105.
https://doi.org/10.1186/s12916-022-02284-6 DOI: https://doi.org/10.1186/s12916-022-02284-6
Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151–61.
https://doi.org/10.1016/S1470-2045(21)00301-6 DOI: https://doi.org/10.1016/S1470-2045(21)00301-6
Helweg-Larsen K. The Danish Register of causes of death. Scand J Public Health. 2011;39(7 Suppl):26–9.
https://doi.org/10.1177/1403494811399958 DOI: https://doi.org/10.1177/1403494811399958
Jensen MB, Laenkholm AV, Offersen BV, Christiansen P, Kroman N, Mouridsen HT, et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016. Acta Oncol. 2018;57(1):13–8.
https://doi.org/10.1080/0284186X.2017.1404638 DOI: https://doi.org/10.1080/0284186X.2017.1404638
Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45. DOI: https://doi.org/10.1200/JCO.2006.09.2775
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.
https://doi.org/10.1200/JCO.2013.50.9984 DOI: https://doi.org/10.1200/JCO.2013.50.9984
Wolff AC, Elizabeth Hale Hammond M, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364–82.
https://doi.org/10.5858/arpa.2018-0902-SA DOI: https://doi.org/10.5858/arpa.2018-0902-SA
Rosso C, Voutsadakis IA. Characteristics, clinical differences and outcomes of breast cancer patients with negative or low HER2 expression. Clin Breast Cancer. 2022;22:391–97.
https://doi.org/10.1016/j.clbc.2022.02.008 DOI: https://doi.org/10.1016/j.clbc.2022.02.008
Kong ZQ, Liu LQ, Huang DQ, Wang YT, Li JJ, Zhang Z, et al. Clinicopathological features and long-term prognostic role of human epidermal growth factor receptor-2 low expression in Chinese patients with early breast cancer: a single-institution study. Biomed Environ Sci. 2024;37(5):457–70.
https://doi.org/10.3967/bes2024.014
Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, et al. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol. 2023;9:500–10.
https://doi.org/10.1001/jamaoncol.2022.7476 DOI: https://doi.org/10.1001/jamaoncol.2022.7476
Pegram M, Jackisch C, Johnston SRD. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. NPJ Breast Cancer. 2023;9(1):1–19.
https://doi.org/10.1038/s41523-023-00533-2 DOI: https://doi.org/10.1038/s41523-023-00533-2
Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, et al. Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ERþ/HER2 mutant breast cancer. Clini Cancer Res. 2019;25(1):277–89.
https://doi.org/10.1158/1078-0432.CCR-18-1544 DOI: https://doi.org/10.1158/1078-0432.CCR-18-1544
Pinhel I, Hills M, Drury S, Salter J, Sumo G, A’Hern R, et al. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res. 2012;14(2):1–12.
https://doi.org/10.1186/bcr3145 DOI: https://doi.org/10.1186/bcr3145
Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol. 2022;8(4):1–4.
https://doi.org/10.1001/jamaoncol.2021.7239 DOI: https://doi.org/10.1001/jamaoncol.2021.7239
Nielsen K, Sode M, Jensen MB, Berg T, Knoop A, Ejlertsen B, et al. High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients. Breast Cancer Res. 2023;25(1):139.
https://doi.org/10.1186/s13058-023-01739-9 DOI: https://doi.org/10.1186/s13058-023-01739-9
Moutafi M, Robbins CJ, Yaghoobi V, Fernandez AI, Martinez-Morilla S, Xirou V, et al. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Lab Invest. 2022;102:1101–8.
https://doi.org/10.1038/s41374-022-00804-9 DOI: https://doi.org/10.1038/s41374-022-00804-9
Cai M, Li M, Lv H, Zhou S, Xu X, Shui R, et al. HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases. BMC Cancer. 2023;23(1):656.
https://doi.org/10.1186/s12885-023-11134-4 DOI: https://doi.org/10.1186/s12885-023-11134-4
Retningslinjer/vejledninger. [cited 2024 Sep 29]. Available from: https://www.dbcg.dk/vaerktoejer/retningslinjer-vejledninger/
Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, et al. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. NPJ Breast Cancer. 2023;9(1):27.
https://doi.org/10.1038/s41523-023-00534-1 DOI: https://doi.org/10.1038/s41523-023-00534-1
Corianò M, Tommasi C, Dinh ATL, Needham J, Aziz H, Joharatnam-Hogan N, et al. The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study. Breast Cancer Res Treat. 2024;206(3):603–14.
https://doi.org/10.1007/s10549-024-07336-4 DOI: https://doi.org/10.1007/s10549-024-07336-4
Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7(1):1.
https://doi.org/10.1038/s41523-020-00208-2 DOI: https://doi.org/10.1038/s41523-020-00208-2
Published
How to Cite
License
Copyright (c) 2023 Michael Sode, Kåre Nielsen, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm
This work is licensed under a Creative Commons Attribution 4.0 International License.
